• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Gastroenterol . Outcomes of Liver Cirrhosis Patients Hospitalized for Influenza Compared With COVID-19 Between 2020 and 2021 in the United St

tetano

Editor, Senior Moderator
J Clin Gastroenterol


. 2025 Jun 12.
doi: 10.1097/MCG.0000000000002199. Online ahead of print. Outcomes of Liver Cirrhosis Patients Hospitalized for Influenza Compared With COVID-19 Between 2020 and 2021 in the United States

Renuka Verma[SUP] 1 [/SUP], Kamleshun Ramphul[SUP] 2 [/SUP], Kyaw M Tun[SUP] 3 [/SUP], Yasmeen Obeidat[SUP] 4 [/SUP], Lily Liu[SUP] 1 [/SUP], Hemamalini Sakthivel[SUP] 5 [/SUP], Tejas Joshi[SUP] 4 [/SUP]



Affiliations
Abstract

Background: Early studies during the COVID-19 pandemic showed that liver cirrhosis patients were at risk of more severe outcomes of the disease. Past studies have also linked cirrhosis patients with poorer influenza outcomes following admissions.
Aim: To compare how patients with liver cirrhosis fared when admitted for COVID-19 as compared with influenza in the United States.
Methods: The National Inpatient Sample (NIS) from 2016 to 2021 was used. The influenza group of cirrhosis patients was extracted for admissions between 2016 and 2019, while the COVID-19 group involved hospitalizations in 2020 and 2021. Baseline characteristics and differences in outcomes were compared between cirrhosis patients with COVID-19 versus influenza.
Results: We recruited 59,590 cirrhosis patients, among whom 6800 (11.4%) had influenza and 52790 (88.6%) were infected with COVID-19. COVID-19 cases were younger, with more patients having dyslipidemia, diabetes, chronic kidney disease (CKD), obesity, and dementia, but fewer patients were smokers, peripheral vascular disease (PVD), history of stroke, history of myocardial infarction, drug abuse, alcohol abuse, chronic ischemic heart disease (IHD), asthma, COPD, and cancer. Our propensity-score matched sample had 6670 cases with COVID-19 and 6670 with influenza. COVID-19 patients were more likely to suffer from hyponatremia, acute myocardial infarction, cardiogenic shock, severe septic shock, mechanical ventilation use, prolonged mechanical ventilation use, cardiac arrest, acute ischemic stroke, acute kidney injury, and all-cause death, but fewer cases with ascites, and hepatorenal syndrome.
Conclusions: The characteristics of cirrhosis patients admitted with COVID-19 differed from those admitted for influenza, with COVID-19 showing a higher mortality risk and varying differences in other complications.

Keywords: COVID-19; United States; influenza; liver cirrhosis; outcomes.

 
Back
Top